Trade Report: Top 10 Cannabis-Based Neurology Innovators in 2025
As cannabinoid-based pharmaceuticals move from fringe therapy to mainstream treatment, a new class of biopharmaceutical innovators is capturing attention from regulators, clinicians, and investors alike. From neurological disorders like refractory epilepsy to inflammation and pain management, cannabis-derived therapies—especially those high in cannabidiol (CBD) and low in tetrahydrocannabinol (THC)—are redefining global drug markets. This report provides […]